Articles

PP01 Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Favreau , K. Venken , S. Faict , dr. K. Maes , K. De Veirman , E. De Bruyne , X. Leleu , D. Elewaut , K. Vanderkerken PhD, E. Menu

Read more

PP1.2 The immunosuppressive role of the adipokine leptin in multiple myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

M. Favreau , K. Venken , E. De Bruyne , E. Van Valckenborgh PhD, dr. K. Maes , K. Vanderkerken PhD, D. Elewaut , E. Menu

Read more

P2.16 Activation of invariant natural killer T cells reduces angiogenesis in the 5T33 multiple myeloma model

BJH - volume 5, issue Abstract Book BHS, january 2014

H. Nur , L. Rao , A. Vacca , D. Elewaut , E. Van Valckenborgh PhD, E. De Bruyne , K. Vanderkerken PhD, E. Menu

Read more

P.27 Invariant Natural Killer T cells in the 5T33 multiple myeloma model

BJH - 2013, issue BHS Abstractbook, january 2013

H. Nur , K. Fostier MD, S. Aspeslagh , W. Renmans , E. Bertrand , X. Leleu , K. Breckpot , R. Schots MD, PhD, M. De Waele , E. Van Valckenborgh PhD, E. De Bruyne , T. Facon , D. Elewaut , K. Vanderkerken PhD, E. Menu

Read more